BioCentury
ARTICLE | Clinical News

Menveo regulatory update

June 20, 2011 7:00 AM UTC

FDA accepted for filing an sBLA from Novartis for Menveo to prevent invasive disease caused by Neisseria meningitides serogroups A, C, Y and W135 in infants and toddlers ages 2 months to 2 years of ag...